Dieser RSV (Palivizumab Biosimilar) Antikörper ist unkonjugiert
Applikation
Flow Cytometry (FACS), In vivo Studies (in vivo)
Verwendungszweck
Palivizumab Biosimilar, RSV Monoclonal Antibody
Spezifität
The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
Produktmerkmale
Recombinant Humanized IgG1 Monoclonal Antibody.
Aufreinigung
Protein A affinity column
Reinheit
> 95% by SDS-PAGE under reducing conditions and HPLC.
Sterilität
0.2 μm filtered
Endotoxin-Niveau
< 1 EU per 1 mg of the protein by the LAL method.
Immunogen
The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
Research Grade
Reaktivität: Human
ELISA
Wirt: Mammalian Cells
Monoclonal
unconjugated
Recombinant Antibody
Applikationshinweise
ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
1 mg/mL
Buffer
PBS, pH 7.4, no stabilizers or preservatives.
Konservierungsmittel
Without preservative
Handhabung
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.